Safe use of platelet GP IIb/IIIa inhibitors

American Heart Journal
J J FergusonC Vassanelli

Abstract

The platelet membrane glycoprotein IIb/IIIa receptor inhibitor abciximab is used for the treatment of patients undergoing high-risk percutaneous coronary interventions and is used in approximately one third of coronary interventions in the United States and a growing number of procedures in Europe. Recent clinical trials have shown that this potent antiplatelet agent significantly reduces the incidence of death and nonfatal myocardial infarction and the need for revascularization. With expanding experience since the commercial release of abciximab in February 1995, several strategies to enhance the safety of abciximab have emerged. In particular, new data confirm that the risk of bleeding-identified as a concern in the original EPIC trial-can be substantially reduced through the use of low-dose adjunctive heparin, early sheath removal, and fastidious postprocedure vascular access site care. Other recommendations for enhancing the safety of potent antiplatelet agents in a variety of clinical situations are provided. The following article reflects insights regarding the safety of glycoprotein IIb/IIIa inhibitors expressed by a group of international experts convened in Davos, Switzerland, February 16, 1997 This report attempts to...Continue Reading

References

Feb 18, 1997·Circulation·S D BerkowitzJ E Tcheng
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators

❮ Previous
Next ❯

Citations

Feb 2, 2000·The Annals of Thoracic Surgery·J H LemmerJ G Hill
Mar 20, 2002·Pharmacotherapy·Chantal PharandDenis Hamel
Aug 2, 2007·Hematology/oncology Clinics of North America·Yu-Min P Shen, Eugene P Frenkel
Mar 5, 2002·Journal of Vascular and Interventional Radiology : JVIR·Richard Shlansky-Goldberg
Mar 1, 2006·Rheumatic Diseases Clinics of North America·Doruk Erkan, Michael D Lockshin
Oct 29, 2005·The American Journal of Cardiology·Sunil V RaoRobert A Harrington
Apr 15, 2004·The American Journal of Cardiology·Jean-Pierre DeryUNKNOWN ReoPro Readministration Registry Investigators
Aug 31, 2000·The Annals of Thoracic Surgery·J H Lemmer
Mar 23, 2000·The American Journal of Cardiology·M MadanJ E Tcheng
Apr 16, 1998·American Heart Journal·A K GoklaneyW B Hillegass
Jan 15, 2003·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·L G Y Claeys, W Berg
Apr 4, 2001·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·M S ReddyD J Kereiakes
Mar 2, 1999·British Journal of Haematology·D H Bevan
Jul 13, 1999·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·H ArjomandD A Mascarenhas
Jul 22, 2004·American Journal of Therapeutics·Ramesh M GowdaTerrence J Sacchi
Mar 23, 2002·International Anesthesiology Clinics·Elamana Vijayakumar
Sep 1, 1999·Current Opinion in Hematology·M MadanS D Berkowitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.